



MAPLE LEAF FOODS INC.

Financial Statements
For the Third Quarter Ended
September 30, 2019

Consolidated Interim Balance Sheets

| <i>(In thousands of Canadian dollars)</i> <i>(Unaudited)</i> | <i>Notes</i> | As at September 30, 2019 | As at September 30, 2018 ⁽ⁱ⁾ | As at December 31, 2018 ⁽ⁱ⁾ |
|---|--------------|-------------------------------------|--|---|
| ASSETS | | | | |
| Current assets | | | | |
| Cash and cash equivalents | | \$ 70,760 | \$ 109,643 | \$ 72,578 |
| Accounts receivable | 3 | 151,479 | 150,232 | 146,283 |
| Notes receivable | 3 | 32,418 | 26,823 | 30,504 |
| Inventories | 4 | 384,115 | 307,495 | 348,901 |
| Biological assets | 5 | 108,558 | 87,935 | 111,493 |
| Income and other taxes recoverable | 13 | 2,107 | — | — |
| Prepaid expenses and other assets | | 37,815 | 17,082 | 38,222 |
| Assets held for sale | 6 | 37,044 | — | — |
| | | \$ 824,296 | \$ 699,210 | \$ 747,981 |
| Property and equipment | | 1,346,625 | 1,152,900 | 1,283,950 |
| Right of use assets | 2(b) | 229,864 | — | — |
| Investment property | | 1,864 | 5,109 | 5,109 |
| Employee benefits | | — | 39,658 | 5,389 |
| Other long-term assets | | 12,769 | 8,212 | 8,074 |
| Goodwill | | 659,612 | 613,178 | 664,879 |
| Intangible assets | | 350,898 | 282,100 | 424,616 |
| Total assets | | \$ 3,425,928 | \$ 2,800,367 | \$ 3,139,998 |
| LIABILITIES AND EQUITY | | | | |
| Current liabilities | | | | |
| Accounts payable and accruals | | \$ 406,697 | \$ 308,288 | \$ 344,460 |
| Current portion of provisions | 7 | 2,701 | 3,917 | 3,457 |
| Current portion of long-term debt | 8 | 887 | 839 | 80,897 |
| Current portion of lease obligations | 2(b) | 39,650 | — | — |
| Income taxes payable | 13 | — | 11,382 | 42,884 |
| Other current liabilities | | 31,166 | 45,042 | 24,031 |
| | | \$ 481,101 | \$ 369,468 | \$ 495,729 |
| Long-term debt | 8 | 472,990 | 174,276 | 302,524 |
| Lease obligations | 2(b) | 205,750 | — | — |
| Employee benefits | | 154,276 | 101,427 | 103,982 |
| Provisions | 7 | 46,020 | 8,937 | 49,895 |
| Other long-term liabilities | | 2,583 | 14,771 | 53,564 |
| Deferred tax liability | 13 | 116,091 | 133,329 | 127,465 |
| Total liabilities | | \$ 1,478,811 | \$ 802,208 | \$ 1,133,159 |
| Shareholders' equity | | | | |
| Share capital | 9 | \$ 851,068 | \$ 820,588 | \$ 849,655 |
| Retained earnings | | 1,120,286 | 1,208,848 | 1,178,389 |
| Contributed surplus | | 4,577 | — | 4,649 |
| Accumulated other comprehensive income (loss) | | 1,564 | (4,891) | 3,532 |
| Treasury stock | | (30,378) | (26,386) | (29,386) |
| Total shareholders' equity | | \$ 1,947,117 | \$ 1,998,159 | \$ 2,006,839 |
| Total liabilities and equity | | \$ 3,425,928 | \$ 2,800,367 | \$ 3,139,998 |

⁽ⁱ⁾ Restated, see Note 18(a).

See accompanying Notes to the Unaudited Condensed Consolidated Interim Financial Statements.

Consolidated Interim Statements of Net Earnings

| <i>(In thousands of Canadian dollars, except share amounts)</i> <i>(Unaudited)</i> | <i>Notes</i> | Three months ended September 30, | | Nine months ended September 30, | |
|---|--------------|---|-------------|--|--------------|
| | | 2019 | 2018 | 2019 | 2018 |
| Sales | | \$ 995,787 | \$ 874,827 | \$ 2,925,576 | \$ 2,601,580 |
| Cost of goods sold | | 856,070 | 756,245 | 2,495,362 | 2,211,571 |
| Gross profit | | \$ 139,717 | \$ 118,582 | \$ 430,214 | \$ 390,009 |
| Selling, general and administrative expenses | | 123,650 | 77,377 | 328,325 | 252,794 |
| Earnings before the following: | | \$ 16,067 | \$ 41,205 | \$ 101,889 | \$ 137,215 |
| Restructuring and other related costs | 7 | 4,588 | — | 5,979 | 3,971 |
| Other expense | 11 | 1,534 | 3,346 | 7,892 | 4,431 |
| Earnings before interest and income taxes | | \$ 9,945 | \$ 37,859 | \$ 88,018 | \$ 128,813 |
| Interest expense and other financing costs | 12 | 8,137 | 2,274 | 24,648 | 5,793 |
| Earnings before income taxes | | \$ 1,808 | \$ 35,585 | \$ 63,370 | \$ 123,020 |
| Income tax (recovery) expense | 13 | (11,601) | 9,029 | 6,199 | 33,621 |
| Net earnings | | \$ 13,409 | \$ 26,556 | \$ 57,171 | \$ 89,399 |
| Earnings per share: | 14 | | | | |
| Basic earnings per share | | \$ 0.11 | \$ 0.21 | \$ 0.46 | \$ 0.71 |
| Diluted earnings per share | | \$ 0.11 | \$ 0.21 | \$ 0.46 | \$ 0.70 |
| Weighted average number of shares (millions) | 14 | | | | |
| Basic | | 123.8 | 124.6 | 123.7 | 125.6 |
| Diluted | | 125.2 | 126.6 | 125.4 | 128.0 |

See accompanying Notes to the Unaudited Condensed Consolidated Interim Financial Statements.

Consolidated Interim Statements of Other Comprehensive Income (Loss)

| (In thousands of Canadian dollars) (Unaudited) | Three months ended September 30, | | Nine months ended September 30, | |
|--|----------------------------------|------------|---------------------------------|------------|
| | 2019 | 2018 | 2019 | 2018 |
| Net earnings | \$ 13,409 | \$ 26,556 | \$ 57,171 | \$ 89,399 |
| Other comprehensive income (loss) | | | | |
| Actuarial gains (losses) that will not be reclassified to profit or loss (Net of tax of \$1.8 million and \$14.1 million; 2018: \$4.1 million and \$13.4 million) | \$ 5,192 | \$ 11,542 | \$ (39,808) | \$ 38,191 |
| Items that are or may be reclassified subsequently to profit or loss: | | | | |
| Change in accumulated foreign currency translation adjustment (Net of tax of \$0.0 million and \$0.0 million; 2018: \$0.0 million and \$0.0 million) | \$ 4,154 | \$ (6,330) | \$ (11,563) | \$ 12,868 |
| Change in foreign exchange (losses) gains on long-term debt designated as a net investment hedge (Net of tax of \$0.6 million and \$1.5 million; 2018: \$0.1 million and \$0.3 million) | (3,505) | 604 | 7,956 | (2,251) |
| Change in unrealized (losses) gains on cash flow hedges (Net of tax of \$0.2 million and \$0.6 million; 2018: \$0.2 million and \$0.7 million) | (461) | 479 | 1,639 | (5,888) |
| Total items that are or may be reclassified subsequently to profit or loss | \$ 188 | \$ (5,247) | \$ (1,968) | \$ 4,729 |
| Total other comprehensive income (loss) | \$ 5,380 | \$ 6,295 | \$ (41,776) | \$ 42,920 |
| Comprehensive income | \$ 18,789 | \$ 32,851 | \$ 15,395 | \$ 132,319 |

See accompanying Notes to the Unaudited Condensed Consolidated Interim Financial Statements.

Consolidated Interim Statements of Changes in Total Equity

| (In thousands of Canadian dollars) (Unaudited) | Note | Share capital | Retained earnings | Contributed surplus | Accumulated other comprehensive income (loss) ⁽ⁱ⁾ | | Treasury stock | Total equity |
|---|------|---------------|-------------------|---------------------|--|---|----------------|--------------|
| | | | | | Foreign currency translation adjustment | Unrealized gains and losses on cash flow hedges | | |
| Balance as at December 31, 2018 | | \$ 849,655 | 1,178,389 | 4,649 | 8,518 | (4,986) | (29,386) | \$ 2,006,839 |
| Impact of new IFRS standards | 2(b) | — | (1,100) | — | — | — | — | (1,100) |
| Net earnings | | — | 57,171 | — | — | — | — | 57,171 |
| Other comprehensive income (loss) ⁽ⁱⁱ⁾ | | — | (39,808) | — | (3,607) | 1,639 | — | (41,776) |
| Dividends declared (\$0.44 per share) | | — | (53,903) | — | — | — | — | (53,903) |
| Share-based compensation expense | 14 | — | — | 13,352 | — | — | — | 13,352 |
| Deferred taxes on share-based compensation | | — | — | 1,160 | — | — | — | 1,160 |
| Obligation for repurchase of shares | 9 | (6,347) | — | (7,556) | — | — | — | (13,903) |
| Exercise of stock options | | 7,760 | — | — | — | — | — | 7,760 |
| Settlement of share-based compensation | | — | (20,463) | (7,028) | — | — | 13,986 | (13,505) |
| Shares purchased by RSU trust | | — | — | — | — | — | (14,978) | (14,978) |
| Balance as at September 30, 2019 | | \$ 851,068 | 1,120,286 | 4,577 | 4,911 | (3,347) | (30,378) | \$ 1,947,117 |

| (In thousands of Canadian dollars) (Unaudited) | Note | Share capital | Retained earnings | Contributed surplus | Accumulated other comprehensive income (loss) ⁽ⁱ⁾ | | Treasury stock | Total equity |
|---|------|---------------|-------------------|---------------------|--|---|----------------|--------------|
| | | | | | Foreign currency translation adjustment | Unrealized gains and losses on cash flow hedges | | |
| Balance as at December 31, 2017 | | \$ 835,154 | 1,253,035 | — | (11,420) | 1,800 | (26,961) | \$ 2,051,608 |
| Impact of new IFRS standards | | — | (3,695) | — | — | — | — | (3,695) |
| Net earnings | | — | 89,399 | — | — | — | — | 89,399 |
| Other comprehensive income (loss) ⁽ⁱⁱ⁾ | | — | 38,191 | — | 10,617 | (5,888) | — | 42,920 |
| Dividends declared (\$0.39 per share) | | — | (49,023) | — | — | — | — | (49,023) |
| Share-based compensation expense | 14 | — | — | 13,785 | — | — | — | 13,785 |
| Deferred taxes on share-based compensation | | — | — | (1,100) | — | — | — | (1,100) |
| Repurchase of shares | 9 | (30,406) | (101,495) | (12,685) | — | — | — | (144,586) |
| Exercise of stock options | | 15,840 | — | — | — | — | — | 15,840 |
| Settlement of share-based compensation | | — | (17,564) | — | — | — | 10,575 | (6,989) |
| Shares purchased by RSU trust | | — | — | — | — | — | (10,000) | (10,000) |
| Balance at September 30, 2018 | | \$ 820,588 | 1,208,848 | — | (803) | (4,088) | (26,386) | \$ 1,998,159 |

⁽ⁱ⁾ Items that are or may be subsequently reclassified to profit or loss.

⁽ⁱⁱ⁾ Included in other comprehensive income (loss) is the change in actuarial gains and losses that will not be reclassified to profit or loss and has been reclassified to retained earnings.

See accompanying Notes to the Unaudited Condensed Consolidated Interim Financial Statements.

Consolidated Interim Statements of Cash Flows

| <i>(In thousands of Canadian dollars)</i> <i>(Unaudited)</i> | Three months ended September 30, | | Nine months ended September 30, | |
|---|----------------------------------|-------------|---------------------------------|--------------|
| | 2019 | 2018 | 2019 | 2018 |
| CASH PROVIDED BY (USED IN): | | | | |
| Operating activities | | | | |
| Net earnings | \$ 13,409 | \$ 26,556 | \$ 57,171 | \$ 89,399 |
| Add (deduct) items not affecting cash: | | | | |
| Change in fair value of biological assets | 1,289 | 5,781 | 13,316 | 33,134 |
| Depreciation and amortization | 44,534 | 30,467 | 130,359 | 90,764 |
| Share-based compensation | 3,948 | 4,547 | 13,352 | 13,785 |
| Deferred income taxes | (2,897) | 7,590 | 2,803 | 23,250 |
| Income tax current | (8,704) | 1,439 | 3,396 | 10,371 |
| Interest expense and other financing costs | 8,137 | 2,274 | 24,648 | 5,793 |
| Loss on sale of long-term assets | 375 | 806 | 1,092 | 4,638 |
| Change in fair value of non-designated derivative financial instruments | (6,450) | 3,818 | 624 | (8,482) |
| Change in net pension liability | 854 | 1,915 | 1,804 | 5,520 |
| Net income taxes paid | (7,172) | (2,154) | (37,956) | (6,424) |
| Interest paid | (7,264) | (1,695) | (21,006) | (4,334) |
| Change in provision for restructuring and other related costs | 3,819 | (2,356) | 3,965 | (6,643) |
| Change in derivatives margin | (721) | (1,702) | 1,804 | 14,583 |
| Other | 2,255 | (2,014) | 2,191 | (6,878) |
| Change in non-cash working capital | 52,360 | 14,926 | (8,528) | (65,752) |
| Cash provided by operating activities | \$ 97,772 | \$ 90,198 | \$ 189,035 | \$ 192,724 |
| Financing activities | | | | |
| Dividends paid | \$ (17,993) | \$ (16,179) | \$ (53,903) | \$ (49,023) |
| Net (decrease) increase in long-term debt | (667) | 118,110 | 99,630 | 162,964 |
| Payment of lease obligation | (8,848) | — | (25,719) | — |
| Exercise of stock options | 4,789 | — | 7,760 | 15,840 |
| Repurchase of shares | — | (68,472) | — | (139,416) |
| Payment of deferred financing fees | (769) | (475) | (5,597) | (554) |
| Purchase of treasury stock | (9,978) | (5,000) | (14,978) | (10,000) |
| Cash (used in) provided by financing activities | \$ (33,466) | \$ 27,984 | \$ 7,193 | \$ (20,189) |
| Investing activities | | | | |
| Additions to long-term assets | \$ (60,544) | \$ (45,070) | \$ (185,960) | \$ (127,971) |
| Acquisition of business, net of cash acquired | — | — | (847) | (138,380) |
| Proceeds from sale of long-term assets | 71 | 34 | 146 | 34 |
| Payment of income tax liabilities assumed on acquisition | — | — | (11,385) | — |
| Cash used in investing activities | \$ (60,473) | \$ (45,036) | \$ (198,046) | \$ (266,317) |
| Increase (decrease) in cash and cash equivalents | \$ 3,833 | \$ 73,146 | \$ (1,818) | \$ (93,782) |
| Cash and cash equivalents, beginning of period | 66,927 | 36,497 | 72,578 | 203,425 |
| Cash and cash equivalents, end of period | \$ 70,760 | \$ 109,643 | \$ 70,760 | \$ 109,643 |

See accompanying Notes to the Unaudited Condensed Consolidated Interim Financial Statements.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

(Tabular amounts in thousands of Canadian dollars unless otherwise indicated)
Three and nine months ended September 30, 2019 and 2018

1. THE COMPANY

Maple Leaf Foods Inc. ("Maple Leaf Foods" or the "Company") is a producer of food products under leading brands including Maple Leaf®, Maple Leaf Prime®, Schneiders®, Mina®, Greenfield Natural Meat Co.®, Lightlife®, Field Roast Grain Meat Co.™ and Swift®. The Company's portfolio includes prepared meats, ready-to-cook and ready-to-serve meals, value-added fresh pork and poultry and plant protein products. The address of the Company's registered office is 6985 Financial Dr. Mississauga, Ontario, L5N 0A1, Canada. The unaudited condensed consolidated interim financial statements ("consolidated financial statements") of the Company as at and for the three and nine months ended September 30, 2019 include the accounts of the Company and its subsidiaries. The Company's results are organized into two segments: the Meat Protein Group and the Plant Protein Group.

2. SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements should be read in conjunction with the Company's 2018 annual audited consolidated financial statements.

(a) Statement of Compliance

The consolidated financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34 *Interim Financial Reporting* as issued by the International Accounting Standards Board ("IASB") and using the accounting policies, determination of significant estimates and judgments, and corresponding accounting treatments consistent with the Company's 2018 annual audited consolidated financial statements, except for new standards adopted during the nine months ended September 30, 2019 as described below.

The consolidated financial statements were authorized for issue by the Board of Directors on October 29, 2019.

(b) Accounting Standards Adopted During the Fiscal Year

Beginning on January 1, 2019, the Company adopted certain International Financial Reporting Standards ("IFRS") and amendments. As required by IAS 34 *Interim Financial Reporting* and IAS 8 *Accounting Policies, Changes in Accounting Estimates and Errors*, the nature and the effect of these changes are disclosed below:

Leases

Beginning on January 1, 2019, the Company adopted IFRS 16 *Leases* using the modified retrospective approach where prior periods are not restated. The new standard replaces IAS 17 *Leases* and provides a new framework for lessee accounting that requires most right of use ("ROU") assets obtained through operating leases to be capitalized and a related liability to be recorded. IFRS 16 substantially carries forward the accounting requirements for lessors. The adoption of IFRS 16 results in changes to property, equipment and vehicle lease contracts which were previously classified as operating leases under IAS 17. Upon adoption, lease obligations equal to the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate are recognized. An ROU asset, representing the Company's right to use the underlying leased asset, will generally be equal to the lease obligation at adoption and subsequently depreciated on a straight-line basis.

Payments previously recognized in the consolidated statements of net earnings (loss) are replaced by a combination of depreciation on the ROU asset and interest expense on the lease obligations. Depreciation is classified as either selling, general and administrative expenses or cost of goods sold, depending on the leased asset's intended use. Interest expense is classified as interest expense and other financing costs. Refer to the Interim Report to Shareholders for the First Quarter Ended March 31, 2019 Note 2(b) for practical expedients elected and the initial impact of adoption.

Uncertainty over Income Tax Treatments

Beginning January 1, 2019, the Company adopted IFRIC 23 *Uncertainty over Income Tax Treatments*. The interpretations provide guidance on how to value uncertain income tax positions based on the probability of whether the relevant tax authorities will accept a company's tax treatments. Refer to the Interim Report to Shareholders for the First Quarter Ended March 31, 2019 Note 2(b) for the initial impact of adoption.

Long-term Interests in Associates and Joint Ventures

Beginning January 1, 2019, the Company adopted amendments to IAS 28 *Investments in Associates and Joint Ventures*. The amendments clarify that a company applies IFRS 9 *Financial Instruments* to long-term interests in an associate or joint venture that form part of the net investment in the associate or joint venture. The Company adopted the amendments to IAS 28 retrospectively in its consolidated financial statements for the annual period beginning January 1, 2019. The adoption of the amendments to IAS 28 did not have a material impact on the consolidated financial statements.

Annual Improvements to IFRS (2015-2017) Cycle

Beginning January 1, 2019, the Company adopted narrow-scope amendments to a total of four standards as part of its annual improvement process. Amendments were made to clarify that a company must remeasure its previously held interest in a joint operation when it obtains control of the business in accordance with IFRS 3 *Business Combinations* but does not remeasure when it obtains joint control of the business under IFRS 11 *Joint Arrangements*. The amendments also include clarification that, all income tax consequences of dividend payments should be recognized consistently with the transactions that generated the distributable profits, under IAS 12 *Income Taxes* and that under IAS 23 *Borrowing Costs*, any specific borrowing that remains outstanding after the related asset is ready for its intended use or sale becomes part of general borrowings. The Company adopted these amendments prospectively in its consolidated financial statements for the annual period beginning January 1, 2019. The adoption of these standards did not have a material impact on the consolidated financial statements.

Employee benefits (amendment)

Beginning January 1, 2019, the Company adopted an amendment to IAS 19 *Employee Benefits*. The amendment clarifies the effect of a plan amendment, curtailment and settlement on the requirements regarding the asset ceiling. In addition, if a plan amendment, curtailment or settlement occurs, it is mandatory under the amended standard that the current service cost and the net interest for the period after the remeasurement are determined using the assumptions used for the remeasurement. The Company adopted the amendment to IAS 19 prospectively in its consolidated financial statements for the annual period beginning January 1, 2019. The amendment to IAS 19 did not have a material impact on the consolidated financial statements.

(c) Accounting Pronouncements Issued But Not Yet Effective*Conceptual Framework*

On March 29, 2018, the IASB issued its revised Conceptual Framework for Financial Reporting. The revised Conceptual Framework does not constitute a substantial revision from the previously effective guidance, but does provide additional guidance on topics not previously covered such as presentation and disclosure. This amendment is effective on January 1, 2020. The Company intends to adopt this amendment in its consolidated financial statements for the annual period beginning January 1, 2020. The adoption of the revised Conceptual Framework for Financial Reporting is not expected to have a material impact on the consolidated financial statements.

Definition of a Business

On October 22, 2018, the IASB issued a narrow scope amendment to IFRS 3 *Business Combinations*. This amendment narrowed and clarified the definition of a business, as well as permitted a simplified assessment of whether an acquired set of activities and assets is a group of assets rather than a business. This amendment effective on January 1, 2020 and is to be applied prospectively. The Company intends to adopt the amendment to IFRS 3 in its consolidated financial statements for the annual period beginning January 1, 2020. The adoption of the amendment to IFRS 3 is not expected to have a material impact on the consolidated financial statements.

Definition of Material

On October 31, 2018, the IASB issued amendments to IAS 1 *Presentation of Financial Statements* and IAS 8 *Accounting Policies, Changes in Accounting Estimates and Errors*. These amendments clarify and align the definition of material and provide guidance to help improve consistency in the application of materiality when used in other IFRS standards. These amendments are effective on January 1, 2020 and are to be applied prospectively. The Company intends to adopt the amendments to IAS 1 and IAS 8 in its consolidated financial statements for the annual period beginning January 1, 2020. The adoption of the amendments to IAS 1 and IAS 8 are not expected to have a material impact on the consolidated financial statements.

3. ACCOUNTS AND NOTES RECEIVABLE

| | As at September 30, 2019 | As at September 30, 2018 | As at December 31, 2018 ⁽ⁱ⁾ |
|---------------------------------------|-------------------------------------|-----------------------------|---|
| Trade receivables | \$ 117,769 | \$ 105,416 | \$ 109,945 |
| Less: Allowance for doubtful accounts | (2,773) | (1,272) | (1,757) |
| Net trade receivables | \$ 114,996 | \$ 104,144 | \$ 108,188 |
| Other receivables: | | | |
| Commodity taxes receivable | 11,400 | 21,630 | 11,394 |
| Government receivable | 13,750 | 13,134 | 15,753 |
| Other | 11,333 | 11,324 | 10,948 |
| | \$ 151,479 | \$ 150,232 | \$ 146,283 |

⁽ⁱ⁾ Restated, see Note 18 (a).

The aging of trade receivables is as follows:

| | As at September 30, 2019 | As at September 30, 2018 | As at December 31, 2018 |
|---------------------|-------------------------------------|-----------------------------|----------------------------|
| Current | \$ 81,430 | \$ 83,559 | \$ 72,605 |
| Past due 0-30 days | 24,888 | 15,096 | 29,830 |
| Past due 31-60 days | 4,230 | 2,251 | 2,677 |
| Past due > 60 days | 7,221 | 4,510 | 4,833 |
| | \$ 117,769 | \$ 105,416 | \$ 109,945 |

Trade receivables are impaired when their estimated future cash flows are less than their contractual cash flows. The amount of impairment takes into account the financial condition of the customers, delinquencies in payments, collaterals and credit insurance coverage on the trade receivables.

On July 19, 2019, the Company amended its three-year accounts receivable securitization facility (the "Securitization Facility") by extending the maturity to July 19, 2022 and increasing the maximum cash advance available to the Company under the Securitization Facility to \$120.0 million (September 30, 2018: \$110.0 million; December 31, 2018: \$110.0 million). The Securitization Facility provides cash funding with a proportion of the Company's receivables being sold, and provides the Company with competitively priced financing and further diversifies its funding sources. Under the Securitization Facility, the Company has sold certain of its trade accounts receivable, with very limited recourse, to an unconsolidated third-party trust financed by an international financial institution with a long-term AA- debt rating, for cash and short-term notes back to the Company. The receivables are sold at a discount to face value based on prevailing money market rates. The Company retains servicing responsibilities for these receivables.

As at September 30, 2019, trade accounts receivable being serviced under the Securitization Facility amounted to \$139.6 million (September 30, 2018: \$134.0 million; December 31, 2018: \$127.4 million). In return for the sale of its trade receivables, the Company will receive cash of \$107.2 million (September 30, 2018: \$107.2 million; December 31, 2018: \$96.9 million) and notes receivable in the amount of \$32.4 million (September 30, 2018: \$26.8 million; December 31, 2018: \$30.5 million). The notes receivable are non-interest bearing and are settled on the settlement dates of the securitized accounts receivable. Due to the timing of receipts and disbursements, the Company may, from time to time, also record a receivable or payable related to the Securitization Facility. As at September 30, 2019, the Company recorded a net payable amount of \$21.0 million (September 30, 2018: \$2.8 million net payable; December 31, 2018: \$32.5 million net payable) in accounts payable and accruals.

The Securitization Facility requires the sale of trade receivables to be treated as a sale from an accounting perspective and as a result, trade receivables sold under this program are derecognized in the consolidated interim balance sheets as at September 30, 2019, September 30, 2018 and the consolidated annual balance sheet as at December 31, 2018.

4. INVENTORIES

| | As at September 30, 2019 | As at September 30, 2018 ⁽ⁱ⁾ | As at December 31, 2018 |
|-----------------|-------------------------------------|--|----------------------------|
| Raw materials | \$ 56,934 | \$ 34,432 | \$ 43,455 |
| Work in process | 35,370 | 27,639 | 27,921 |
| Finished goods | 222,986 | 186,634 | 216,520 |
| Packaging | 19,395 | 17,174 | 15,017 |
| Spare parts | 49,430 | 41,616 | 45,988 |
| | \$ 384,115 | \$ 307,495 | \$ 348,901 |

⁽ⁱ⁾ Restated, see Note 18(a).

For the three months ended September 30, 2019, inventory in the amount of \$784.9 million (2018: \$670.9 million) was expensed through cost of goods sold.

For the nine months ended September 30, 2019, inventory in the amount of \$2,292.7 million (2018: \$1,981.6 million) was expensed through cost of goods sold.

5. BIOLOGICAL ASSETS

The change in fair value of commercial hog stock for the three months ended September 30, 2019 was a loss of \$1.3 million (2018: loss of \$5.8 million) and was recorded in cost of goods sold.

The change in fair value of commercial hog stock for the nine months ended September 30, 2019 was a loss of \$13.3 million (2018: loss of \$33.1 million) and was recorded in cost of goods sold.

The fair value measures of commercial hog stock have been categorized as a Level 3 fair value based on inputs to the valuation techniques used. There were no transfers between levels during the three and nine months ended September 30, 2019 and September 30, 2018.

6. ASSETS HELD FOR SALE

Assets held for sale are those relating to a poultry plant and associated quota in Drummondville, Québec and vacant plants located in Thamesford, Ontario and St. Anselme, Québec.

7. PROVISIONS

| | Restructuring and related provisions | | | | | Total |
|--|--------------------------------------|--------------------|------------------------|---------------------------|---------------------------------------|-----------|
| | Legal | Environ- mental | Lease make- good | Employee related costs | Site closing and other costs | |
| Balance as at December 31, 2018⁽ⁱ⁾ | \$ 289 | 4,762 | 1,810 | 43,820 | 2,671 | \$ 53,352 |
| Impact of new IFRS standards ⁽ⁱⁱ⁾ | — | — | (1,810) | — | (2,400) | (4,210) |
| Charges | — | — | — | 1,385 | 2 | 1,387 |
| Cash payments | — | (25) | — | (582) | (62) | (669) |
| Non-cash items | — | — | — | — | (5) | (5) |
| Balance as at March 31, 2019 | \$ 289 | 4,737 | — | 44,623 | 206 | \$ 49,855 |
| Charges | — | — | — | 624 | 30 | 654 |
| Reversals | — | — | — | (3,470) | — | (3,470) |
| Cash payments | — | (4) | — | (571) | (30) | (605) |
| Non-cash items | — | — | — | — | (98) | (98) |
| Balance as at June 30, 2019 | \$ 289 | 4,733 | — | 41,206 | 108 | \$ 46,336 |
| Charges | — | — | — | 3,635 | 8 | 3,643 |
| Reversals | — | — | — | (467) | — | (467) |
| Cash payments | — | (21) | — | (763) | (7) | (791) |
| Balance as at September 30, 2019 | \$ 289 | 4,712 | — | 43,611 | 109 | \$ 48,721 |
| Current | | | | | | \$ 2,701 |
| Non-current | | | | | | 46,020 |
| Total as at September 30, 2019 | | | | | | \$ 48,721 |

⁽ⁱ⁾ Balance as at December 31, 2018, includes current portion of \$3.5 million and non-current portion of \$49.9 million.

⁽ⁱⁱ⁾ See Note 2(b).

Restructuring and Other Related Costs

During the three months ended September 30, 2019, the Company recorded restructuring and other related costs of \$4.6 million (2018: \$0.0 million). Of this amount, \$1.4 million related to accelerated depreciation, and \$0.9 million related to employee related costs, as a result of the previously announced future closures of the Brampton, Toronto and St. Mary's poultry plants. The remaining \$2.3 million related to employee related costs for other organizational restructuring initiatives in the quarter.

During the nine months ended September 30, 2019, the Company recorded restructuring and the other related costs of \$6.0 million (2018: \$4.0 million). Of this amount, \$4.3 million related to accelerated depreciation, offset by \$0.6 million related to net reversals of employee related costs, as a result of the previously announced future closures of the Brampton, Toronto and St. Mary's poultry plants. The remaining \$2.3 million related to employee related costs for other organizational restructuring initiatives in the quarter.

| | Legal | Environ- mental | Lease make- good | Restructuring and related provisions | | Total |
|----------------------------------|--------|--------------------|------------------------|---|---------------------------------------|-----------|
| | | | | Severance and other employee related costs | Site closing and other costs | |
| Balance as at December 31, 2017 | \$ 289 | 4,833 | 2,228 | 10,379 | 2,879 | \$ 20,608 |
| Charges | — | — | — | 2,106 | 416 | 2,522 |
| Reversals | — | — | (372) | (1,562) | — | (1,934) |
| Cash payments | — | (8) | — | (2,233) | (407) | (2,648) |
| Non-cash items | — | — | — | — | 30 | 30 |
| Balance as at March 31, 2018 | \$ 289 | 4,825 | 1,856 | 8,690 | 2,918 | \$ 18,578 |
| Charges | — | — | — | 1,532 | 977 | 2,509 |
| Reversals | — | — | — | (59) | (86) | (145) |
| Cash payments | — | (15) | (27) | (4,486) | (1,131) | (5,659) |
| Non-cash items | — | — | — | — | 29 | 29 |
| Balance as at June 30, 2018 | \$ 289 | 4,810 | 1,829 | 5,677 | 2,707 | \$ 15,312 |
| Charges | — | — | — | 31 | 785 | 816 |
| Reversals | — | — | (18) | (909) | — | (927) |
| Cash payments | — | (17) | (1) | (1,558) | (798) | (2,374) |
| Non-cash items | — | — | — | — | 27 | 27 |
| Balance as at September 30, 2018 | \$ 289 | 4,793 | 1,810 | 3,241 | 2,721 | \$ 12,854 |
| Current | | | | | | \$ 3,917 |
| Non-current | | | | | | 8,937 |
| Total as at September 30, 2018 | | | | | | \$ 12,854 |

8. LONG-TERM DEBT

| | As at September 30, 2019 | As at September 30, 2018 | As at December 31, 2018 |
|--|-----------------------------|-----------------------------|----------------------------|
| Revolving line of credit up to \$1,300.0 million | \$ — | \$ 166,469 | \$ 374,775 |
| U.S. term credit up to \$351.0 million (US\$265.0 million) | 350,953 | — | — |
| Canadian term credit up to \$350.0 million | 115,000 | — | — |
| Government loans | 7,924 | 8,646 | 8,646 |
| Total long-term debt | \$ 473,877 | \$ 175,115 | \$ 383,421 |
| Current | \$ 887 | \$ 839 | \$ 80,897 |
| Non-current | 472,990 | 174,276 | 302,524 |
| Total long-term debt | \$ 473,877 | \$ 175,115 | \$ 383,421 |

On April 30, 2019, the Company entered into a new syndicated credit facility (the "Credit Facility") consisting of a \$1,300.0 million unsecured committed revolving line of credit maturing April 30, 2024 and two unsecured committed term credit facilities for US\$265.0 million and \$350.0 million maturing April 30, 2024 and April 30, 2023, respectively. The Credit Facility refinanced and replaced the Company's previous \$250.0 million and \$400.0 million unsecured committed revolving credit facilities, which were due to mature on November 7, 2019 and October 19, 2021, respectively. The Credit Facility can be drawn in Canadian or U.S. dollars and bears interest payable monthly, based on Banker's Acceptance and Prime rates for Canadian dollar loans and the London Inter-bank Offered Rate ("Libor") for U.S. dollar loans. The Credit Facility is intended to meet the Company's funding requirements for capital investments, including the construction of its two new manufacturing facilities in London, Ontario and Shelbyville, Indiana, in addition to providing appropriate levels of liquidity and for general corporate purposes. In addition to loans, as at September 30, 2019, the Company had drawn letters of credit of \$6.4 million on the Credit Facility (September 30, 2018: \$6.1 million on the previous facility; December 31, 2018: \$6.3 million on the previous facility).

The Credit Facility requires the maintenance of certain covenants. As at September 30, 2019, the Company was in compliance with all of these covenants.

The Company has additional uncommitted credit facilities for issuing letters of credit up to a maximum of \$125.0 million (September 30, 2018: \$125.0 million; December 31, 2018: \$125.0 million). As at September 30, 2019, \$79.4 million of letters of credit has been issued thereon (September 30, 2018: \$71.5 million; December 31, 2018: \$72.2 million).

The Company has various government loans on specific projects, with interest rates ranging from non-interest bearing to 2.9% per annum (September 30, 2018: 2.9%; December 31, 2018: 2.9%). These facilities are repayable over various terms from 2022 to 2024. All of these facilities are committed.

The following table reconciles the changes in cash flows from financing activities for long-term debt for the period in the respective years:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|------------|
| | 2019 | 2018 | 2019 | 2018 |
| Total long-term debt, beginning of period | \$ 470,295 | \$ 57,630 | \$ 383,421 | \$ 9,248 |
| Revolving and term credit facilities - net drawings | \$ — | \$ 118,730 | \$ 100,621 | \$ 163,908 |
| Government loans - repayments | (667) | (620) | (991) | (944) |
| Total cash flow from long-term debt financing activities | \$ (667) | \$ 118,110 | \$ 99,630 | \$ 162,964 |
| Foreign exchange revaluation | \$ 4,161 | \$ (724) | \$ (9,443) | \$ 2,561 |
| Other non-cash changes | 88 | 99 | 269 | 342 |
| Total non-cash changes | \$ 4,249 | \$ (625) | \$ (9,174) | \$ 2,903 |
| Total long-term debt, as at September 30 | \$ 473,877 | \$ 175,115 | \$ 473,877 | \$ 175,115 |
| Current | \$ 887 | \$ 839 | \$ 887 | \$ 839 |
| Non-current | 472,990 | 174,276 | 472,990 | 174,276 |
| Total long-term debt, as at September 30 | \$ 473,877 | \$ 175,115 | \$ 473,877 | \$ 175,115 |

9. SHARE CAPITAL

Share Repurchase

On May 17, 2019, the Toronto Stock Exchange ("TSX") accepted the Company's notice of intention to commence a Normal Course Issuer Bid ("NCIB"), allowing the Company to repurchase, at its discretion, up to 7.5 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 24, 2019 and will terminate on May 23, 2020, or on such earlier date as the Company completes its purchases pursuant to the notice of intention. Under this bid, during the three and nine months ended September 30, 2019, no shares were purchased for cancellation.

On May 22, 2018, the TSX accepted the Company's notice of intention to commence an NCIB, which allowed the Company to repurchase, at its discretion, up to 7.8 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company were cancelled. The program commenced on May 24, 2018 and was terminated on May 23, 2019 as the Company completed its purchase and cancellation of 4.0 million common shares for \$126.6 million at a volume weighted average price of \$31.82 per common share. Under this bid during the three and nine months ended September 30, 2019, no shares were purchased for cancellation. During the three months ended September 30, 2018, 2.1 million shares were purchased for cancellation for \$68.5 million at a volume weighted average price paid of \$31.97 per common share. During the nine months ended September 30, 2018, 3.1 million shares were purchased for cancellation for \$99.5 million at a volume weighted average price paid of \$31.70 per common share.

On May 17, 2017, the TSX accepted the Company's notice of intention to commence an NCIB, which allowed the Company to repurchase, at its discretion, up to 8.2 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 23, 2017 and was terminated on May 22, 2018 as the Company completed its purchase and cancellation of 3.6 million common shares for \$117.3 million at a volume weighted average price of \$32.51 per common share. Under this bid during the three months ended September 30, 2018, no shares were purchased for cancellation. During the nine months ended September 30, 2018, 1.3 million shares were purchased for cancellation for \$39.9 million at a volume weighted average price paid of \$31.17 per common share.

The Company entered into an Automatic Share Purchase Plan ("ASPP") with a broker that allows the purchase of common shares for cancellation under the NCIB at any time during predetermined trading blackout periods. As at September 30, 2019, an obligation for the repurchase of shares of \$13.9 million (September 30, 2018: \$29.7 million; December 31, 2018: \$0.0 million) was recognized under the ASPP.

Dividends

On October 29, 2019, the Board of Directors approved a dividend of \$0.145 per share payable December 31, 2019 to shareholders of record at the close of business on December 6, 2019.

10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT ACTIVITIES

The Company applies hedge accounting and uses derivatives and other non-derivative financial instruments to manage its exposures to fluctuations in foreign exchange rates and commodity prices.

The fair values and notional amounts of derivative financial instruments as at September 30 are shown below:

| | 2019 | | | 2018 | | |
|--|--------------------------------|-----------------------|---------------------------|--------------------------------|-----------------------|---------------------------|
| | Notional amount ⁽ⁱ⁾ | Fair value | | Notional amount ⁽ⁱ⁾ | Fair value | |
| | | Asset ⁽ⁱⁱ⁾ | Liability ⁽ⁱⁱ⁾ | | Asset ⁽ⁱⁱ⁾ | Liability ⁽ⁱⁱ⁾ |
| Cash flow hedges | | | | | | |
| Foreign exchange contracts | \$ 36,413 | \$ 187 | \$ 95 | \$ 43,027 | \$ 214 | \$ 172 |
| Commodity contracts | \$ — | — | — | \$ 4,802 | — | 165 |
| | | \$ 187 | \$ 95 | | \$ 214 | \$ 337 |
| Fair value hedges⁽ⁱⁱⁱ⁾ | | | | | | |
| Foreign exchange contracts | \$ 84,905 | \$ 294 | \$ 107 | \$ 27,716 | \$ 318 | \$ 57 |
| Commodity contracts | \$ 87,138 | 4,024 | — | \$ 26,718 | — | 379 |
| | | \$ 4,318 | \$ 107 | | \$ 318 | \$ 436 |
| Derivatives not designated in a formal hedging relationship | | | | | | |
| Foreign exchange contracts | \$ 174,811 | \$ 621 | \$ 154 | \$ 128,476 | \$ 433 | \$ 862 |
| Commodity contracts | \$ 183,427 | 2,005 | 372 | \$ 159,331 | 6,960 | — |
| | | \$ 2,626 | \$ 526 | | \$ 7,393 | \$ 862 |
| Total fair value^(iv) | | \$ 7,131 | \$ 728 | | \$ 7,925 | \$ 1,635 |
| Current ^{(i),(iv),(v)} | | \$ 7,131 | \$ 728 | | \$ 7,925 | \$ 1,635 |
| Non-current ⁽ⁱⁱ⁾ | | — | — | | — | — |
| Total fair value | | \$ 7,131 | \$ 728 | | \$ 7,925 | \$ 1,635 |

⁽ⁱ⁾ Unless otherwise stated, notional amounts are stated at the contractual Canadian dollar equivalent.

⁽ⁱⁱ⁾ The current portion of derivative assets and liabilities are recorded in prepaid expenses and other assets and other current liabilities, respectively, in the consolidated interim balance sheets. The long-term portion of derivative assets and liabilities are recorded in other long-term assets and other long-term liabilities, respectively, in the consolidated interim balance sheets.

⁽ⁱⁱⁱ⁾ The carrying amount of the hedged items in the consolidated interim balance sheets are recorded at the inverse of the associated hedging instruments and are equal to the accumulated fair value hedge adjustments less hedge ineffectiveness.

^(iv) Derivatives are short-term and will impact profit or loss at various dates within the next 12 months.

^(v) As at September 30, 2019, the above fair value of current assets has been decreased on the consolidated balance sheet by an amount of \$3.0 million (September 30, 2018: decrease of \$4.7 million; December 31, 2018: decrease of \$1.1 million), which represents the excess of the fair market value of exchange traded commodities contracts over the initial margin requirements. The excess or deficit in maintenance margin requirements with the futures exchange is net settled in cash each day and is therefore presented as cash and cash equivalents.

During the three months ended September 30, 2019, the Company recorded a loss of \$1.3 million (2018: gain of \$0.2 million) on non-designated financial instruments held for trading.

During the nine months ended September 30, 2019, the Company recorded a gain of \$11.8 million (2018: gain of \$8.3 million) on non-designated financial instruments held for trading.

During the three months ended September 30, 2019, the pre-tax amount of hedge ineffectiveness recognized in other expense was a gain of \$0.1 million (2018: gain of \$0.1 million).

During the nine months ended September 30, 2019, the pre-tax amount of hedge ineffectiveness recognized in other expense was a loss of \$0.1 million (2018: gain of \$0.1 million).

The table below sets out fair value measurements of financial instruments using the fair value hierarchy as at September 30, 2019:

| | Level 1 | Level 2 | Level 3 | Total |
|----------------------------|-----------------|--------------|----------|-----------------|
| Assets: | | | | |
| Foreign exchange contracts | \$ — | 1,102 | — | \$ 1,102 |
| Commodity contracts | 5,861 | 168 | — | 6,029 |
| | \$ 5,861 | 1,270 | — | \$ 7,131 |
| Liabilities: | | | | |
| Foreign exchange contracts | \$ — | 356 | — | \$ 356 |
| Commodity contracts | — | 372 | — | 372 |
| | \$ — | 728 | — | \$ 728 |

There were no transfers between levels during the three and nine months ended September 30, 2019 and September 30, 2018. Determination of fair value and the resulting hierarchy requires the use of observable market data whenever available and is consistent with the methodology used in the 2018 annual audited consolidated financial statements. The classification of a financial instrument in the hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. For financial instruments that are recognized at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization at the end of each reporting period.

Accumulated other comprehensive income (loss)

The Company estimates that \$0.1 million, net of tax of \$0.0 million, of unrealized gains included in accumulated other comprehensive income (loss) will be reclassified into net earnings within the next 12 months. The actual amount of this reclassification will be impacted by future changes in the fair value of financial instruments designated as cash flow hedges. The actual amount reclassified could differ from this estimated amount.

During the three months ended September 30, 2019, a gain of approximately \$0.2 million, net of tax of \$0.1 million, was released to earnings from accumulated other comprehensive income (loss) and included in the net change for the period (2018: loss of approximately \$0.4 million, net of tax of \$0.1 million).

During the nine months ended September 30, 2019, a loss of approximately \$1.9 million, net of tax of \$0.7 million, was released to earnings from accumulated other comprehensive income (loss) and included in the net change for the period (2018: loss of approximately \$0.0 million, net of tax of \$0.0 million).

As at September 30, 2019, the Company had US\$265.0 million (September 30, 2018: US\$120.0 million; December 31, 2018: US\$216.0 million) drawn on the Credit Facility (see Note 8) that is designated as a net investment hedge of the Company's U.S. operations. Foreign exchange gains and losses on the designated drawings are recorded in shareholders' equity in the foreign currency translation adjustment component of accumulated other comprehensive income and offset translation adjustments on the underlying net assets of the U.S. operations, which are also recorded in accumulated other comprehensive income (loss).

During the three months ended September 30, 2019, the loss on the net investment hedge recorded in other comprehensive income (loss) was \$3.5 million, net of tax of \$0.6 million (2018: gain of \$0.6 million, net of tax of \$0.1 million).

During the nine months ended September 30, 2019, the gain on the net investment hedge recorded in other comprehensive income (loss) was \$8.0 million, net of tax of \$1.5 million (2018: loss of \$2.3 million, net of tax \$0.3 million).

11. OTHER EXPENSE

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|----------------------------------|----------|---------------------------------|----------|
| | 2019 | 2018 | 2019 | 2018 |
| Loss on disposal of property and equipment | \$ 375 | \$ 587 | \$ 1,092 | \$ 4,638 |
| Net investment property expense | 37 | 155 | 860 | 380 |
| Interest income | (2) | (28) | (4) | (174) |
| Legal and other fees on transactions | 311 | 1,907 | 3,686 | 5,138 |
| Insurance proceeds | — | (327) | — | (7,250) |
| Other legal (reversal) expense | (77) | 786 | 642 | 1,359 |
| Other | 890 | 266 | 1,616 | 340 |
| | \$ 1,534 | \$ 3,346 | \$ 7,892 | \$ 4,431 |

12. INTEREST EXPENSE AND OTHER FINANCING COSTS

| | Three months ended September 30, | | Nine months ended September 30, | |
|---|----------------------------------|----------|---------------------------------|----------|
| | 2019 | 2018 | 2019 | 2018 |
| Interest on borrowings from Credit Facility | \$ 4,298 | \$ 602 | \$ 12,779 | \$ 1,319 |
| Interest on lease obligations | 2,255 | 64 | 6,780 | 194 |
| Interest on securitized receivables | 736 | 694 | 2,082 | 1,742 |
| Interest on government loans | 88 | 99 | 269 | 343 |
| Deferred finance charges | 410 | 287 | 1,092 | 862 |
| Other interest charges | 1,120 | 528 | 2,029 | 1,333 |
| Interest capitalized | (770) | — | (1,339) | — |
| Write-off of deferred finance fees | — | — | 956 | — |
| | \$ 8,137 | \$ 2,274 | \$ 24,648 | \$ 5,793 |

13. INCOME TAXES

Income tax (recovery) expense in the three and nine months ended September 30, 2019 includes (i) a deferred income tax recovery recorded on the remeasurement of deferred tax liabilities at a lower rate; (ii) an adjustment to tax expense for prior periods; and (iii) a recovery for the favourable resolution of an income tax audit.

14. EARNINGS PER SHARE

Basic earnings per share amounts are calculated by dividing the net earnings of the Company by the weighted average number of shares outstanding during the period.

Diluted earnings per share amounts are calculated by dividing the net earnings of the Company by the weighted average number of shares outstanding during the period, adjusted for the effects of potentially dilutive instruments.

The following table sets forth the calculation of basic and diluted earnings per share (“EPS”):

| | 2019 | | | 2018 | | |
|---|--------------|--|---------|--------------|--|---------|
| | Net earnings | Weighted average number of shares ⁽ⁱ⁾ | EPS | Net earnings | Weighted average number of shares ⁽ⁱ⁾ | EPS |
| <i>Three months ended September 30,</i> | | | | | | |
| Basic | \$ 13,409 | 123.8 | \$ 0.11 | \$ 26,556 | 124.6 | \$ 0.21 |
| Stock options ⁽ⁱⁱ⁾ | | 1.4 | | | 2.0 | |
| Diluted | \$ 13,409 | 125.2 | \$ 0.11 | \$ 26,556 | 126.6 | \$ 0.21 |
| <i>Nine months ended September 30,</i> | | | | | | |
| Basic | \$ 57,171 | 123.7 | \$ 0.46 | \$ 89,399 | 125.6 | \$ 0.71 |
| Stock options ⁽ⁱⁱ⁾ | | 1.7 | | | 2.4 | |
| Diluted | \$ 57,171 | 125.4 | \$ 0.46 | \$ 89,399 | 128.0 | \$ 0.70 |

⁽ⁱ⁾ In millions.

⁽ⁱⁱ⁾ Excludes the effect of approximately 1.1 million (2018: 1.5 million) options and performance shares for the three months ended September 30, 2019 and 2.0 million (2018: 1.3 million) for the nine months ended September 30, 2019 that are anti-dilutive.

15. SHARE-BASED PAYMENT

Stock Options

A summary of the status of the Company’s outstanding stock options and changes during the nine months ended September 30 are presented below:

| | 2019 | | 2018 | |
|--------------------------------------|---------------------|---------------------------------|---------------------|---------------------------------|
| | Options outstanding | Weighted average exercise price | Options outstanding | Weighted average exercise price |
| Outstanding at January 1 | 3,976,300 | \$ 25.38 | 4,556,400 | \$ 20.23 |
| Granted | 1,039,200 | \$ 28.38 | 717,300 | \$ 32.50 |
| Exercised | — | \$ — | (10,200) | \$ 20.95 |
| Outstanding at March 31 | 5,015,500 | \$ 26.01 | 5,263,500 | \$ 21.90 |
| Exercised | (137,400) | \$ 21.62 | (1,327,400) | \$ 11.77 |
| Outstanding at June 30 | 4,878,100 | \$ 26.13 | 3,936,100 | \$ 25.32 |
| Granted | — | \$ — | 40,200 | \$ 31.57 |
| Exercised | (221,000) | \$ 21.67 | — | \$ — |
| Outstanding at September 30 | 4,657,100 | \$ 26.34 | 3,976,300 | \$ 25.38 |
| Options currently exercisable | 2,868,900 | \$ 24.14 | 2,450,000 | \$ 22.44 |

All outstanding stock options vest and become exercisable over a period not exceeding five years (time vesting) from the date of grant. The outstanding options have a term of seven years.

At grant date, each option series is measured at fair value based on the Black-Scholes formula. Expected volatility is estimated by considering historic average share price volatility. The inputs used in this model for the options granted during the nine months ended September 30, 2019 and 2018 are shown in the table below⁽ⁱ⁾:

| | Nine months ended September 30, | |
|--|--|-------------|
| | 2019 | 2018 |
| Share price at grant date | \$28.05 | \$32.13 |
| Exercise price | \$28.38 | \$32.45 |
| Expected volatility | 21.3% | 21.4% |
| Option life (in years) ⁽ⁱⁱ⁾ | 4.5 | 4.5 |
| Expected dividend yield | 2.1% | 1.6% |
| Risk-free interest rate ⁽ⁱⁱⁱ⁾ | 1.8% | 2.0% |

⁽ⁱ⁾ Weighted average based on number of units granted.

⁽ⁱⁱ⁾ Expected weighted average life.

⁽ⁱⁱⁱ⁾ Based on Government of Canada bonds.

The fair value of options granted during the three months ended September 30, 2019 was \$0.0 million (2018: \$0.2 million). Expenses relating to current and prior year options during the three months ended September 30, 2019 were \$1.1 million (2018: \$1.0 million).

The fair value of options granted during the nine months ended September 30, 2019 was \$4.4 million (2018: \$4.1 million). Expenses relating to current and prior year options during the nine months ended September 30, 2019 were \$3.2 million (2018: \$2.8 million).

Restricted Share Units and Performance Share Units

A summary of the status of the Company's Restricted Share Units ("RSUs") plans (including Performance Share Units ("PSUs")) and changes during the nine months ended September 30 are presented below:

| | 2019 | | 2018 | |
|------------------------------------|-----------------------------|---|-----------------------------|---|
| | RSUs outstanding | Weighted average fair value at grant | RSUs outstanding | Weighted average fair value at grant |
| Outstanding at January 1 | 1,471,662 | \$ 28.48 | 1,561,695 | \$ 25.61 |
| Granted | 460,450 | \$ 26.26 | 355,770 | \$ 30.65 |
| Exercised | — | \$ — | (69,537) | \$ 22.45 |
| Forfeited | — | \$ — | (3,290) | \$ 25.86 |
| Outstanding at March 31 | 1,932,112 | \$ 27.95 | 1,844,638 | \$ 26.70 |
| Granted | 6,240 | \$ 34.03 | — | \$ — |
| Exercised | (671,658) | \$ 26.33 | (386,252) | \$ 20.56 |
| Forfeited | (63,609) | \$ 28.38 | (21,854) | \$ 23.29 |
| Outstanding at June 30 | 1,203,085 | \$ 28.86 | 1,436,532 | \$ 28.41 |
| Granted | 70,330 | \$ 27.53 | 38,830 | \$ 30.83 |
| Forfeited | (5,820) | \$ 27.35 | (890) | \$ 25.17 |
| Outstanding at September 30 | 1,267,595 | \$ 28.79 | 1,474,472 | \$ 28.47 |

The fair value of RSUs and PSUs granted during the three months ended September 30, 2019 was \$1.7 million (2018: \$1.1 million). Expenses for the three months ended September 30, 2019 relating to current and prior year RSUs and PSUs were \$2.5 million (2018: \$3.2 million).

The fair value of RSUs and PSUs granted during the nine months ended September 30, 2019 was \$12.4 million (2018: \$10.2 million). Expenses for the nine months ended September 30, 2019 relating to current and prior year RSUs and PSUs were \$9.1 million (2018: \$9.8 million).

The key assumptions used in the valuation of RSUs granted during the nine months ended September 30, 2019 and 2018 are shown in the table below⁽ⁱ⁾:

| | 2019 | 2018 |
|------------------------------|-------|-------|
| Expected RSU life (in years) | 3.1 | 3.1 |
| Forfeiture rate | 12.6% | 16.1% |
| Risk-free discount rate | 1.7% | 1.9% |

⁽ⁱ⁾ Weighted average based on number of units granted.

Director Share Units

The fair value of director share units expensed during the three and nine months ended September 30, 2019 were \$0.3 million and \$1.0 million (2018: \$0.4 million and \$1.2 million), respectively.

16. RELATED PARTY TRANSACTIONS

The Company sponsors a number of defined benefit and defined contribution plans. During the three and nine months ended September 30, 2019, the Company's contributions to these plans were \$7.2 million and \$22.5 million (2018: \$7.1 million and \$21.6 million), respectively.

The Company's largest shareholder is McCain Capital Inc. ("MCI") which is beneficially owned or controlled by Mr. Michael H. McCain, Chief Executive Officer and President of the Company. For the three and nine months ended September 30, 2019, the Company received services from MCI in the amount of \$0.1 million and \$0.4 million (2018: \$0.1 million and \$0.3 million), respectively, which represented the market value of the transactions with MCI. As at September 30, 2019, \$0.1 million (September 30, 2018: \$0.2 million; December 31, 2018: \$0.4 million) was owing to MCI relating to these transactions.

McCain Financial Advisory Services ("MFAS") is an entity jointly controlled by individuals including Mr. Michael H. McCain. For the three and nine months ended September 30, 2019 and 2018, the Company provided services to, and received from, MFAS for a nominal amount, which represented the market value of the transactions.

17. SEGMENTED FINANCIAL INFORMATION

Reportable Segmented Information

During the three months ended September 30, 2019, the Company completed a comprehensive analysis of the role of its rapidly expanding plant protein business in the Company's meat and plant protein portfolio, their respective financial profiles and long-term value creation opportunities. Based on the importance of these two distinct businesses and differing strategic and financial requirements to maximize their market leadership and long-term shareholder value, the Company has disaggregated its business into two operating segments. As described below, these segments offer different products, with separate organizational structures, brands, financial and marketing strategies. The Company's chief operating decision makers regularly review internal reports for these businesses; performance of the Meat Protein Group is based on revenue growth, Adjusted Operating Earnings and Adjusted EBITDA, while the performance of the Plant Protein Group is based predominately on revenue growth rates, while managing gross margins and controlling investment levels which generate high revenue growth rates. Refer to the section, Non-IFRS Financial Measures, of the Company's Management's Discussion and Analysis for the third quarter ended September 30, 2019, for the definitions of these non-IFRS financial measures. The operations of each segment are described as follows:

- (a) The Meat Protein Group is comprised of prepared meats, ready-to-cook and ready-to-serve meals, hog production and value-added fresh pork and poultry products that are sold to retail, foodservice and industrial channels. The Meat Protein Group includes leading brands such as Maple Leaf®, Maple Leaf Prime®, Schneiders®, Mina®, Greenfield Natural Meat Co.®, Swift® and many leading sub-brands.
- (b) The Plant Protein Group is comprised of refrigerated plant protein products, premium grain-based protein and vegan cheese products sold to retail, foodservice and industrial channels. The Plant Protein Group includes the leading brands Lightlife® and Field Roast Grain Meat Co.™.

| | Three months ended September 30, 2019 | | | | Three months ended September 30, 2018 ⁽ⁱ⁾ | | | |
|--|---------------------------------------|---------------------|-------------------------------|------------|--|---------------------|-------------------------------|------------|
| | Meat Protein Group | Plant Protein Group | Non-Allocated ⁽ⁱⁱ⁾ | Total | Meat Protein Group | Plant Protein Group | Non-Allocated ⁽ⁱⁱ⁾ | Total |
| Sales | \$ 953,306 | 46,998 | (4,517) | \$ 995,787 | \$ 838,709 | 36,118 | — | \$ 874,827 |
| Gross profit | \$ 123,351 | 9,995 | 6,371 | \$ 139,717 | \$ 119,342 | 9,056 | (9,816) | \$ 118,582 |
| Selling, general and administrative expenses | \$ 78,783 | 44,867 | — | \$ 123,650 | \$ 68,750 | 8,627 | — | \$ 77,377 |
| Earnings (loss) before income taxes | \$ 39,617 | (34,925) | (2,884) | \$ 1,808 | \$ 50,293 | 384 | (15,092) | \$ 35,585 |
| Interest expense and other financing costs | — | — | 8,137 | 8,137 | — | — | 2,274 | 2,274 |
| Other expense | 363 | 53 | 1,118 | 1,534 | 299 | 45 | 3,002 | 3,346 |
| Restructuring and other related costs | 4,588 | — | — | 4,588 | — | — | — | — |
| Earnings (loss) from operations | \$ 44,568 | (34,872) | 6,371 | \$ 16,067 | \$ 50,592 | 429 | (9,816) | \$ 41,205 |
| Decrease in fair value of biological assets ⁽ⁱⁱⁱ⁾ | — | — | 1,289 | 1,289 | — | — | 5,781 | 5,781 |
| Unrealized (gain) loss on derivative contracts ^(iv) | — | — | (7,660) | (7,660) | — | — | 4,035 | 4,035 |
| Adjusted Operating Earnings | \$ 44,568 | (34,872) | — | \$ 9,696 | \$ 50,592 | 429 | — | \$ 51,021 |
| Depreciation and amortization | 41,225 | 3,309 | — | 44,534 | 28,794 | 1,661 | — | 30,455 |
| Items included in other expense representative of ongoing operations | (363) | (53) | (392) | (808) | (299) | (45) | — | (344) |
| Adjusted EBITDA | \$ 85,430 | (31,616) | (392) | \$ 53,422 | \$ 79,087 | 2,045 | — | \$ 81,132 |

⁽ⁱ⁾ Comparative figures have been presented to align with current reportable segments.

⁽ⁱⁱ⁾ Non-Allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of expenses not separately identifiable to reportable segments and are not part of the measures used by the Company when assessing a segment's operating results.

⁽ⁱⁱⁱ⁾ Refer to Note 5 for further details regarding biological assets.

^(iv) Unrealized gains/losses on derivative contracts are reported within cost of goods sold.

| | Nine months ended September 30, 2019 | | | | Nine months ended September 30, 2018 ⁽ⁱ⁾ | | | |
|---|--------------------------------------|---------------------|-------------------------------|--------------|---|---------------------|-------------------------------|--------------|
| | Meat Protein Group | Plant Protein Group | Non-Allocated ⁽ⁱⁱ⁾ | Total | Meat Protein Group | Plant Protein Group | Non-Allocated ⁽ⁱⁱ⁾ | Total |
| Sales | \$ 2,807,699 | 126,673 | (8,796) | \$ 2,925,576 | \$ 2,500,830 | 100,750 | — | \$ 2,601,580 |
| Gross profit | \$ 417,507 | 27,815 | (15,108) | \$ 430,214 | \$ 385,034 | 29,386 | (24,411) | \$ 390,009 |
| Selling, general and administrative expenses | \$ 254,679 | 73,646 | — | \$ 328,325 | \$ 228,071 | 24,723 | — | \$ 252,794 |
| Earnings (loss) before income taxes | \$ 155,923 | (45,979) | (46,574) | \$ 63,370 | \$ 156,081 | 4,437 | (37,498) | \$ 123,020 |
| Interest expense and other financing costs | — | — | 24,648 | 24,648 | — | — | 5,793 | 5,793 |
| Other expense (income) | 926 | 148 | 6,818 | 7,892 | (3,089) | 226 | 7,294 | 4,431 |
| Restructuring and other related costs | 5,979 | — | — | 5,979 | 3,971 | — | — | 3,971 |
| Earnings (loss) from operations | \$ 162,828 | (45,831) | (15,108) | \$ 101,889 | \$ 156,963 | 4,663 | (24,411) | \$ 137,215 |
| Decrease in fair value of biological assets ⁽ⁱⁱⁱ⁾ | — | — | 13,316 | 13,316 | — | — | 33,134 | 33,134 |
| Unrealized loss (gain) on derivative contracts ^(iv) | — | — | 1,792 | 1,792 | — | — | (8,723) | (8,723) |
| Adjusted Operating Earnings | \$ 162,828 | (45,831) | — | \$ 116,997 | \$ 156,963 | 4,663 | — | \$ 161,626 |
| Depreciation and amortization | 121,054 | 9,305 | — | 130,359 | 85,504 | 5,229 | — | 90,733 |
| Items included in other (expense) income representative of ongoing operations | (926) | (148) | (392) | (1,466) | 3,089 | (226) | — | 2,863 |
| Adjusted EBITDA | \$ 282,956 | (36,674) | (392) | \$ 245,890 | \$ 245,556 | 9,666 | — | \$ 255,222 |

⁽ⁱ⁾ Comparative figures have been presented to align with current reportable segments.

⁽ⁱⁱ⁾ Non-Allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of expenses not separately identifiable to reportable segments and are not part of the measures used by the Company when assessing a segment's operating results.

⁽ⁱⁱⁱ⁾ Refer to Note 5 for further details regarding biological assets.

^(iv) Unrealized gains/losses on derivative contracts are reported within cost of goods sold.

The following summarizes capital expenditures by segments:

| | Three months ended September 30, | | Nine months ended September 30, | |
|------------------------------------|----------------------------------|-----------|---------------------------------|------------|
| | 2019 | 2018 | 2019 | 2018 |
| Capital expenditures | | | | |
| Meat Protein Group | \$ 48,319 | \$ 36,225 | \$ 153,018 | \$ 106,591 |
| Plant Protein Group | 7,168 | 4,075 | 19,951 | 8,132 |
| Non-allocated capital expenditures | 5,057 | 4,770 | 12,991 | 13,248 |
| | \$ 60,544 | \$ 45,070 | \$ 185,960 | \$ 127,971 |

Information About Geographic Areas

The following summarizes sales by country of origin:

| | Three months ended September 30, | | Nine months ended September 30, | |
|--------------|----------------------------------|------------|---------------------------------|--------------|
| | 2019 | 2018 | 2019 | 2018 |
| Canada | \$ 748,708 | \$ 646,314 | \$ 2,185,002 | \$ 1,920,078 |
| U.S. | 106,442 | 92,655 | 297,832 | 264,400 |
| Japan | 95,783 | 90,333 | 274,865 | 259,441 |
| Other | 44,854 | 45,525 | 167,877 | 157,661 |
| Sales | \$ 995,787 | \$ 874,827 | \$ 2,925,576 | \$ 2,601,580 |

The following summarizes non-current assets by country:

| | As at September 30, 2019 | | As at September 30, 2018 ⁽ⁱ⁾ | | As at December 31, 2018 ⁽ⁱ⁾ |
|--|-----------------------------|----|--|----|---|
| Canada | \$ 2,207,716 | \$ | 1,917,984 | \$ | 1,999,244 |
| U.S. | 393,354 | | 143,351 | | 387,215 |
| Other | 562 | | 164 | | 169 |
| Total non-current assets⁽ⁱⁱ⁾ | \$ 2,601,632 | \$ | 2,061,499 | \$ | 2,386,628 |

⁽ⁱ⁾ Restated, see Note 18(a).

⁽ⁱⁱ⁾ Excludes financial instruments, employee benefits and deferred tax assets.

Information About Major Customers

For the three months ended September 30, 2019, the Meat Protein Group and Plant Protein Group reported combined sales to two customers representing 11.5% and 10.7% (2018: two customers representing 12.5% and 10.9%) of total Company sales. No other sales were made to any one customer that represented in excess of 10% of total sales.

For the nine months ended September 30, 2019, the Meat Protein Group and Plant Protein Group reported combined sales to two customers representing 11.1% and 10.5% (2018: two customers representing 12.4% and 11.1%) of total Company sales. No other sales were made to any one customer that represented in excess of 10% of total sales.

18. BUSINESS COMBINATIONS

(a) 2018 Acquisitions

VIAU Food Products Inc.

On November 13, 2018, the Company acquired 100% of the outstanding shares of VIAU Food Products Inc. ("VIAU"), a privately held Canadian market leader in premium Italian cooked, dry-cured and charcuterie meats, for a purchase price of \$215.0 million. The Company financed the transaction using a combination of drawings on existing credit facilities and equity.

Recognized goodwill is attributable to VIAU's assembled workforce combined with its considerable expertise, product development knowledge and skills. No portion of goodwill is deductible for tax purposes.

The fair value of consideration transferred for the acquisition of VIAU consists of the following:

| | Purchase price November 13, 2018 |
|-------------------------------------|---|
| Agreed-upon purchase price | \$ 215,000 |
| Working capital adjustments | (12,790) |
| Reduction for liabilities assumed | (4,456) |
| Total consideration | \$ 197,754 |
| Consideration paid in cash | \$ 168,953 |
| Consideration paid in common shares | \$ 28,801 |

During the second quarter of 2019, the Company finalized amounts recorded in the business combination which resulted in the following adjustments to the preliminary purchase price allocation:

| | November 13, 2018 | | |
|-----------------------------------|--------------------------------|--------------------|----------------------|
| | Preliminary amounts | Adjustments | Final amounts |
| Current Assets | | | |
| Cash | \$ 6,930 | — | \$ 6,930 |
| Accounts receivable | 12,383 | (353) | 12,030 |
| Inventories | 32,096 | — | 32,096 |
| Prepaid expenses and other assets | 1,566 | — | 1,566 |
| Non-current assets | | | |
| Property and equipment | 85,579 | — | 85,579 |
| Goodwill | 17,601 | 17,599 | 35,200 |
| Intangible assets | 81,632 | (4,800) | 76,832 |
| Current liabilities | | | |
| Accounts payable and accruals | (19,877) | — | (19,877) |
| Current income tax liabilities | (11,186) | (199) | (11,385) |
| Other current liabilities | (1,294) | — | (1,294) |
| Non-current liabilities | | | |
| Other long-term liabilities | (3,123) | — | (3,123) |
| Deferred tax liability | (5,400) | (11,400) | (16,800) |
| Total net assets acquired | \$ 196,907 | 847 | \$ 197,754 |

Cericola Farms Inc.

On October 22, 2018, the Company acquired two poultry plants and associated supply from Cericola Farms Inc. ("Cericola"), a privately held Canadian company. The purchase price of the assets was \$80.0 million, with a put/call option to purchase a third processing facility for a purchase price of \$40.0 million, exercisable within three years. The Company financed the transaction using existing credit facilities. The acquisition has been accounted for as a business combination.

The amount of goodwill deductible for tax purposes is \$6.2 million.

The fair value of consideration transferred for the two poultry plants and associated supply acquired from Cericola Farms consists of the following:

| | Purchase price |
|---|-------------------------|
| | October 22, 2018 |
| Agreed-upon purchase price | \$ 80,000 |
| Cash deposit on purchase of third processing facility | (20,185) |
| Working capital adjustments | 226 |
| Total consideration paid in cash | \$ 60,041 |
| Consideration paid in cash | \$ 59,815 |
| Consideration payable | \$ 226 |

During the second quarter of 2019, the Company finalized amounts recorded in the business combination which resulted in the following adjustments to the preliminary purchase price allocation:

| | October 22, 2018 | | |
|-----------------------------------|------------------------|-------------|------------------|
| | Preliminary amounts | Adjustments | Final amounts |
| Current Assets | | | |
| Accounts receivable | \$ 5,748 | (99) | \$ 5,649 |
| Inventories | 980 | — | 980 |
| Prepaid expenses and other assets | 56 | — | 56 |
| Non-current assets | | | |
| Property and equipment | 17,702 | 281 | 17,983 |
| Goodwill | 6,688 | (441) | 6,247 |
| Intangible assets | 31,910 | — | 31,910 |
| Current liabilities | | | |
| Accounts payable and accruals | (3,269) | 485 | (2,784) |
| Total net assets acquired | \$ 59,815 | 226 | \$ 60,041 |

The Field Roast Grain Meat Company, SPC

On January 29, 2018, the Company acquired 100% of the outstanding shares of The Field Roast Grain Meat Company, SPC ("Field Roast Grain Meat Co."), a privately held U.S. based corporation engaged in the production and distribution of premium grain-based protein and vegan cheese products, for a purchase price of \$140.2 million. The Company financed the transaction using a combination of cash-on-hand and drawings on existing credit facilities.

Recognized goodwill is attributable to Field Roast Grain Meat Co.'s leadership position in the fast-growing plant protein market combined with its considerable expertise, product development knowledge and skills. No portion of goodwill is deductible for tax purposes.

The fair value of consideration transferred for the acquisition of Field Roast Grain Meat Co. consists of the following:

| | Purchase price January 29, 2018 |
|---------------------------------------|------------------------------------|
| Agreed-upon purchase price | \$ 147,906 |
| Working capital adjustments | (1,787) |
| Reduction for liabilities assumed | (5,949) |
| Total consideration | \$ 140,170 |
| Consideration paid in cash | \$ 138,755 |
| Contingent consideration paid in cash | \$ 1,415 |

During the fourth quarter of 2018, the Company finalized amounts recorded in the business combination which resulted in the following adjustments to the preliminary purchase price allocation:

| | January 29, 2018 | | |
|------------------------------------|------------------------|-------------|-------------------|
| | Preliminary amounts | Adjustments | Final amounts |
| Current Assets | | | |
| Cash | \$ 375 | — | \$ 375 |
| Accounts receivable | 3,302 | — | 3,302 |
| Inventories | 6,332 | 863 | 7,195 |
| Income and other taxes recoverable | 336 | — | 336 |
| Prepaid expenses and other assets | 354 | — | 354 |
| Non-current assets | | | |
| Property and equipment | 5,080 | — | 5,080 |
| Goodwill | 137,777 | (50,944) | 86,833 |
| Intangible assets | — | 66,558 | 66,558 |
| Current liabilities | | | |
| Accounts payable and accruals | (9,634) | — | (9,634) |
| Other current liabilities | (638) | — | (638) |
| Non-current liabilities | | | |
| Other long-term liabilities | (2,212) | — | (2,212) |
| Deferred tax liability | (902) | (16,477) | (17,379) |
| Total net assets acquired | \$ 140,170 | — | \$ 140,170 |

The consolidated interim balance sheet as at September 30, 2018 has been re-stated to reflect the adjustments to the purchase price allocations above.

(b) Transaction Costs

During the three months ended September 30, 2019, the Company recorded legal and other transaction costs of \$0.3 million (2018: \$1.9 million) related to acquisition activities that have been recognized in other expense.

During the nine months ended September 30, 2019, the Company recorded legal and other transaction costs of \$3.7 million (2018: \$5.1 million) related to acquisition activities that have been recognized in other expense.